Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Voriconazole hepatotoxicity in severe liver dysfunction.

Solís-Muñoz P, López JC, Bernal W, Willars C, Verma A, Heneghan MA, Wendon J, Auzinger G.

J Infect. 2013 Jan;66(1):80-6. doi: 10.1016/j.jinf.2012.09.011. Epub 2012 Oct 3.

PMID:
23041040
2.

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.

Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdière M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J; National Institute of Allergy and Infectious Diseases Mycoses Study Group.

N Engl J Med. 2002 Jan 24;346(4):225-34. Erratum in: N Engl J Med. 2007 Feb 15;356(7):760.

3.

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group.

N Engl J Med. 2002 Aug 8;347(6):408-15.

4.

Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation.

Amigues I, Cohen N, Chung D, Seo SK, Plescia C, Jakubowski A, Barker J, Papanicolaou GA.

Biol Blood Marrow Transplant. 2010 Jan;16(1):46-52. doi: 10.1016/j.bbmt.2009.08.015. Epub 2009 Oct 9.

5.

Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.

[No authors listed]

Prescrire Int. 2004 Feb;13(69):13-6.

PMID:
15055210
6.

Case collection study of the safety of AmBisome in association with voriconazole in the treatment of patients with invasive fungal infection.

Askari E, Jarque I, Nicolás Franco S, Cáceres Agra JJ.

Rev Esp Quimioter. 2010 Dec;23(4):210-2. No abstract available.

7.

Evaluation of hepatotoxicity with off-label oral-treatment doses of voriconazole for invasive fungal infections.

Gorski E, Esterly JS, Postelnick M, Trifilio S, Fotis M, Scheetz MH.

Antimicrob Agents Chemother. 2011 Jan;55(1):184-9. doi: 10.1128/AAC.01078-10. Epub 2010 Oct 25.

8.

Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.

Shehab N, DePestel DD, Mackler ER, Collins CD, Welch K, Erba HP.

Pharmacotherapy. 2007 Jul;27(7):970-9.

PMID:
17594202
9.

Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections.

den Hollander JG, van Arkel C, Rijnders BJ, Lugtenburg PJ, de Marie S, Levin MD.

J Antimicrob Chemother. 2006 Jun;57(6):1248-50. Epub 2006 Mar 23.

10.

Lack of cross-hepatotoxicity between voriconazole and posaconazole.

Foo H, Gottlieb T.

Clin Infect Dis. 2007 Sep 15;45(6):803-5. No abstract available.

11.

Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B?

Pagano L, Valentini CG, Fianchi L, Caira M.

J Chemother. 2011 Feb;23(1):5-8. Review.

PMID:
21482486
12.

Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.

Sambatakou H, Dupont B, Lode H, Denning DW.

Am J Med. 2006 Jun;119(6):527.e17-24.

PMID:
16750972
13.

Management of voriconazole hepatotoxicity in a lung transplant patient.

Belaiche S, Roustit M, Bedouch P, Quetant S, Saint-Raymond C, Pison C.

Transpl Infect Dis. 2011 Jun;13(3):309-11. doi: 10.1111/j.1399-3062.2010.00590.x. Epub 2010 Dec 22.

PMID:
21176020
14.

The hepatotoxicity of antifungal medications in bone marrow transplant recipients.

Fischer MA, Winkelmayer WC, Rubin RH, Avorn J.

Clin Infect Dis. 2005 Aug 1;41(3):301-7. Epub 2005 Jun 24.

15.

Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.

Ament AJ, Hübben MW, Verweij PE, de Groot R, Warris A, Donnelly JP, van 't Wout J, Severens JL.

J Antimicrob Chemother. 2007 Aug;60(2):385-93. Epub 2007 Jun 7.

16.

Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.

Patterson TF, Boucher HW, Herbrecht R, Denning DW, Lortholary O, Ribaud P, Rubin RH, Wingard JR, DePauw B, Schlamm HT, Troke P, Bennett JE; European Organization for Research and Treatment of Cancer (EORTC) Invasive Fungal Infections Group (IFIG); Pfizer Global Aspergillus Study Group.

Clin Infect Dis. 2005 Nov 15;41(10):1448-52. Epub 2005 Oct 13.

17.

The role of voriconazole in the treatment of central nervous system blastomycosis.

Ta M, Flowers SA, Rogers PD.

Ann Pharmacother. 2009 Oct;43(10):1696-700. doi: 10.1345/aph.1M010. Epub 2009 Sep 1. Review.

PMID:
19724015
18.

Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity.

Suzuki Y, Tokimatsu I, Sato Y, Kawasaki K, Sato Y, Goto T, Hashinaga K, Itoh H, Hiramatsu K, Kadota J.

Clin Chim Acta. 2013 Sep 23;424:119-22. doi: 10.1016/j.cca.2013.05.025. Epub 2013 Jun 6.

PMID:
23747486
19.

Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.

Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Ghahramani P, Hodges M, Groll AH, Perfect JR.

Pediatr Infect Dis J. 2002 Mar;21(3):240-8.

PMID:
12005089
20.

Risk factors for voriconazole hepatotoxicity at 12 weeks in lung transplant recipients.

Luong ML, Hosseini-Moghaddam SM, Singer LG, Chaparro C, Azad S, Lazar N, Boutros PC, Keshavjee S, Rotstein C, Husain S.

Am J Transplant. 2012 Jul;12(7):1929-35. doi: 10.1111/j.1600-6143.2012.04042.x. Epub 2012 Apr 5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk